Literature DB >> 1096811

Antibacterial activity of cinoxacin in vitro.

H Giamarellou, G G Jackson.   

Abstract

Cinoxacin is a new synthetic compound similar chemically and in antimicrobial activity to oxolonic acid and nalidixic acid. It is most effective against Escherichia coli and Proteus mirabilis, but at concentrations expected in the urine it is inhibitory for all species of Enterobacteriaceae. Relative to nalidixic acid, cinoxacin has slightly greater inhibitory and bactericidal activity, less inoculum effect probably due to less heterogeneity in the susceptibility of bacterial cells, and less inhibition by high concentrations of serum protein. Both drugs are more active in an acid than an alkaline medium. Glucose can specifically antagonize the inhibitory effect against P. mirabilis. In urine the bactericidal rate and effect are decreased. Resistance to cinoxacin can be developed quickly by serial transfers in vitro. Some nonresistant organisms remained viable in bactericidal drug concentrations. The in vivo importance of the favorable features of cinoxacin must be determined by clinical trials.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1096811      PMCID: PMC429204          DOI: 10.1128/AAC.7.5.688

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  4 in total

1.  Serum versus urinary antimicrobial concentrations in cure of urinary-tract infections.

Authors:  T A Stamey; W R Fair; M M Timothy; M A Millar; G Mihara; Y C Lowery
Journal:  N Engl J Med       Date:  1974-11-28       Impact factor: 91.245

2.  Compound 64716, a new synthetic antibacterial agent.

Authors:  W E Wick; D A Preston; W A White; R S Gordee
Journal:  Antimicrob Agents Chemother       Date:  1973-10       Impact factor: 5.191

3.  Cinoxacin: in vitro antibacterial studies of a new synthetic organic acid.

Authors:  R M Lumish; C W Norden
Journal:  Antimicrob Agents Chemother       Date:  1975-02       Impact factor: 5.191

4.  Cinoxacin: effectiveness against experimental pyelonephritis in rats.

Authors:  D H Holmes; P W Ensminger; R S Gordee
Journal:  Antimicrob Agents Chemother       Date:  1974-10       Impact factor: 5.191

  4 in total
  11 in total

1.  [A comparison of cinoxacin and nalidixic acid in the treatment of chronic urinary tract infections].

Authors:  H Briedigkeit; R Schimmelpfennig; R Buder; K Precht; H Dröseler
Journal:  Infection       Date:  1982       Impact factor: 3.553

2.  Efficacy of cinoxacin in urinary tract infections.

Authors:  A P Panwalker; H Giamarellou; G G Jackson
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191

3.  Comparative in vitro studies of cinoxacin, nalidixic acid, and oxolinic acid.

Authors:  R C Gordon; L I Stevens; C E Edmiston; K Mohan
Journal:  Antimicrob Agents Chemother       Date:  1976-12       Impact factor: 5.191

4.  Comparative pharmacokinetic profiles of cinoxacin and pipemidic acid in humans.

Authors:  J M Brogard; F Comte; J Lavillaureix
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1983 Jul-Sep       Impact factor: 2.441

5.  In vitro antimicrobial activity of cinoxacin against 2,968 clinical bacterial isolates.

Authors:  R N Jones; P C Fuchs
Journal:  Antimicrob Agents Chemother       Date:  1976-07       Impact factor: 5.191

6.  Pharmacology of cinoxacin in humans.

Authors:  H R Black; K S Israel; R L Wolen; G L Brier; B D Obermeyer; E A Ziege; J D Wolny
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

7.  In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.

Authors:  A Bauernfeind; C Petermüller
Journal:  Eur J Clin Microbiol       Date:  1983-04       Impact factor: 3.267

8.  Norfloxacin versus cotrimoxazole in the treatment of lower urinary tract infections.

Authors:  H Giamarellou; J Tsagarakis; G Petrikkos; G K Daikos
Journal:  Eur J Clin Microbiol       Date:  1983-06       Impact factor: 3.267

Review 9.  Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections.

Authors:  T S Sisca; R C Heel; J A Romankiewicz
Journal:  Drugs       Date:  1983-06       Impact factor: 9.546

10.  Influence of probenecid on serum levels and urinary excretion of cinoxacin.

Authors:  N Rodriguez; P O Madsen; P G Welling
Journal:  Antimicrob Agents Chemother       Date:  1979-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.